Devic’s Syndrome Treatment Market size was valued at USD 210.00 million in 2018 to USD 246.32 million in 2024 and is anticipated to reach USD 374.34 million by 2032, at a CAGR of 5.45% during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2023
Base Year
2024
Forecast Period
2025-2032
Devic’s Syndrome Treatment Market Size 2024
USD 246.32 Million
Devic’s Syndrome Treatment Market, CAGR
5.45%
Devic’s Syndrome Treatment Market Size 2032
USD 374.34 Million
The Devic’s Syndrome Treatment Market is shaped by leading players such as Alexion Pharmaceuticals, F. Hoffmann-La Roche, Viela Bio, Chugai Pharmaceutical, and Teva Pharmaceutical Industries. These companies maintain strong portfolios across biologics, immunotherapies, and cost-effective treatment solutions, reinforcing their competitive edge through product innovation, regulatory approvals, and strategic collaborations. Alexion remains at the forefront with advanced biologic therapies, while Roche and Chugai continue to expand their monoclonal antibody pipelines. Viela Bio has strengthened its position with novel treatment launches, and Teva supports accessibility through affordable immunosuppressants. Regionally, North America leads the market with a 44.9% share in 2024, driven by advanced healthcare infrastructure, strong reimbursement policies, and early adoption of innovative biologic therapies.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
The Devic’s Syndrome Treatment Market grew from USD 210.00 million in 2018 to USD 246.32 million in 2024, projected to reach USD 374.34 million by 2032.
Monoclonal antibodies lead with 42% share, followed by immunosuppressants, corticosteroids, plasma exchange, and supportive therapy, reflecting the dominance of biologics in relapse prevention.
Hospital pharmacies hold 55% share, making them the leading distribution channel, while retail pharmacies and online pharmacies support long-term care and patient convenience.
Hospitals dominate end-user share at 50%, with specialty clinics and home healthcare providers contributing significantly to ongoing care management and supportive therapies.
North America leads with 44.9% market share in 2024, supported by advanced healthcare infrastructure, strong reimbursement policies, and early adoption of biologic therapies.
Market Segment Insights
By Type Segment
In the Devic’s Syndrome Treatment Market, monoclonal antibodies dominate with around 42% share, driven by strong efficacy in relapse prevention and rising approvals of advanced biologics. Immunosuppressants follow with nearly 25%, sustained by affordability and broad use in maintenance therapy. Corticosteroids account for about 18%, remaining vital in acute management of relapses. Plasma exchange holds approximately 9%, reserved for severe episodes requiring urgent intervention, while supportive therapy represents nearly 6%, focused on symptom relief and quality-of-life improvement.
For instance, Alexion Pharmaceuticals gained FDA approval for Ultomiris (ravulizumab) for NMOSD, reinforcing its position as a long-acting complement inhibitor with proven relapse risk reduction.
By Distribution Channel Segment
Hospital pharmacies lead the distribution channel with a commanding 55% share, reflecting their role in administering complex biologics and plasma exchange drugs under specialist care. Retail pharmacies contribute close to 28%, largely from prescriptions for corticosteroids and immunosuppressants used in long-term care. Online pharmacies account for about 17%, supported by the growth of telemedicine, home delivery services, and rising patient convenience preferences.
By End-User Segment
Among end-users, hospitals dominate with nearly 50% share, owing to their critical role in acute episode management, including intravenous corticosteroid administration and plasma exchange procedures. Specialty clinics secure about 30%, reflecting their importance in ongoing care management, regular monitoring, and biologic therapy delivery. Home healthcare providers hold close to 20%, driven by the shift of supportive therapies and select biologics into patient-centric home settings.
For instance, Cleveland Clinic expanded access to biologic therapies by integrating advanced infusion services at its specialty clinics, enabling precise administration and monitoring.
Key Growth Drivers
Rising Prevalence of Neuromyelitis Optica Spectrum Disorder (NMOSD)
The increasing global prevalence of neuromyelitis optica spectrum disorder, commonly associated with Devic’s Syndrome, is driving demand for advanced treatment options. Growing awareness and improved diagnostic capabilities have led to higher detection rates, ensuring that more patients gain access to targeted therapies. The rise in patient population has encouraged pharmaceutical companies to prioritize research and development in monoclonal antibodies and immunosuppressants, which are now widely considered frontline treatments. This prevalence surge strengthens the overall market outlook.
For instance, Alexion’s Ultomiris (ravulizumab) entered Phase 3 clinical trials for NMOSD, extending its portfolio of complement inhibitors beyond paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome
Advancements in Biologic Therapies
The market benefits significantly from rapid advancements in biologic therapies, particularly monoclonal antibodies. These treatments demonstrate higher efficacy in preventing relapses and improving patient outcomes compared to traditional therapies. Regulatory approvals of drugs such as eculizumab and inebilizumab have transformed clinical practice, establishing biologics as standard-of-care options in many regions. Continuous innovation, coupled with expanding clinical trials for next-generation biologics, is expected to further strengthen adoption. This scientific progress not only enhances patient safety but also ensures long-term commercial growth for biopharmaceutical companies.
For instance, AstraZeneca received U.S. FDA approval for Ultomiris (ravulizumab) for adult patients with neuromyelitis optica spectrum disorder, expanding the reach of next-generation complement inhibitors.
Supportive Government and Reimbursement Policies
Government support and favorable reimbursement policies are key growth drivers in the Devic’s Syndrome Treatment Market. Many countries are implementing reimbursement schemes to reduce patient cost burden, thereby expanding access to advanced therapies such as biologics. Financial incentives for orphan disease treatment development are also encouraging pharmaceutical firms to invest in niche markets. Additionally, healthcare authorities are collaborating with patient advocacy groups to improve awareness and accessibility. These initiatives are reinforcing treatment adoption across developed and emerging markets, fueling consistent growth momentum.
Key Trends & Opportunities
Growing Shift Toward Personalized Medicine
The trend toward personalized medicine is reshaping the Devic’s Syndrome Treatment Market. Clinicians increasingly rely on genetic and biomarker testing to identify patient subgroups most likely to respond to specific therapies. This approach reduces trial-and-error prescribing, improves treatment efficiency, and enhances safety profiles. Pharmaceutical companies are exploring companion diagnostics in tandem with biologics, enabling better patient stratification. This trend not only advances clinical outcomes but also opens new commercial opportunities in precision therapies designed for rare autoimmune disorders such as Devic’s Syndrome.
For instance, Genentech received FDA approval for Enspryng (satralizumab-mwge), a biologic therapy targeting specific immune pathways in NMOSD, alongside companion diagnostic strategies to identify eligible patients more precisely.
Expansion of Digital Health and Telemedicine Integration
Telemedicine adoption offers significant opportunities for improving patient care in Devic’s Syndrome management. Remote consultations, e-prescriptions, and online pharmacy integration provide greater accessibility, particularly for patients in remote or underserved areas. Digital platforms also enable continuous monitoring of treatment outcomes and adherence, strengthening long-term disease control. Pharmaceutical companies and healthcare providers are increasingly leveraging digital health solutions to support home delivery of therapies and patient engagement programs. This integration is expected to enhance market reach and optimize healthcare delivery efficiency.
For instance, Novartis partnered with the digital health platform Ada Health to integrate AI-driven symptom tracking and remote patient support tools into immunological and rare disease care pathways.
Key Challenges
High Cost of Biologic Therapies
The substantial cost of biologic therapies, particularly monoclonal antibodies, presents a major challenge. These treatments often exceed the affordability range of patients in developing markets, limiting access despite clinical benefits. Even in developed regions, reimbursement hurdles can delay or restrict availability. The high pricing structure also places pressure on healthcare systems managing chronic autoimmune disorders. Unless cost-effective alternatives or biosimilars are developed, pricing barriers will continue to hinder market penetration and prevent equitable global access to advanced therapies.
Limited Awareness and Diagnostic Delays
Delayed diagnosis remains a critical challenge in managing Devic’s Syndrome effectively. Limited awareness among both patients and primary healthcare providers often results in misdiagnosis or late-stage identification. This diagnostic lag increases the risk of severe relapses, leading to irreversible disability and higher treatment costs. Awareness gaps are especially prominent in emerging markets where specialized neurology services are scarce. Strengthening physician education programs and expanding access to diagnostic tools are vital for improving early detection and subsequent treatment outcomes.
Dependency on Specialized Infrastructure
The treatment of Devic’s Syndrome often requires specialized infrastructure such as infusion centers, plasma exchange units, and advanced hospital facilities. This dependency creates barriers in regions with limited healthcare infrastructure and trained professionals. Rural and low-resource settings face challenges in delivering timely and effective care. The lack of standardized treatment centers further limits widespread adoption of advanced biologics and plasma therapies. Overcoming this challenge will require significant healthcare investments and cross-sector collaboration to expand infrastructure capacity globally.
Regional Analysis
North America
North America dominates the Devic’s Syndrome Treatment Market with a 44.9% share in 2024. The region benefits from advanced healthcare infrastructure, strong presence of leading pharmaceutical companies, and early adoption of biologic therapies. Robust reimbursement frameworks and high awareness levels support strong uptake of monoclonal antibodies and plasma exchange. With revenues increasing from USD 95.13 million in 2018 to an expected USD 167.47 million by 2032, the region is projected to grow at a CAGR of 5.4%. Continuous R&D investments and expanding clinical trials further enhance the regional outlook.
Europe
Europe ranks second in market share, accounting for 24.4% in 2024. Growth is supported by favorable reimbursement policies, well-established healthcare systems, and high adoption of innovative biologics across major markets such as Germany, France, and the UK. The regional market is expected to rise from USD 53.34 million in 2018 to USD 86.00 million by 2032, reflecting a steady CAGR of 4.7%. Increasing collaborations between pharmaceutical companies and research institutes are expected to accelerate product development and maintain Europe’s strong market position.
Asia Pacific
Asia Pacific is the fastest-growing region, holding 19.5% share in 2024 and expanding at a CAGR of 6.9%. Rising healthcare investments, larger patient population, and rapid adoption of advanced therapies are fueling growth. Countries such as China, Japan, and India are key contributors, driven by improved diagnostic capabilities and government initiatives to expand treatment access. Market revenues are projected to increase from USD 38.75 million in 2018 to USD 82.13 million by 2032. The region’s strong growth outlook highlights significant opportunities for global and regional pharmaceutical companies.
Latin America
Latin America contributes 5.0% of the market in 2024, supported by growing awareness of rare neurological disorders and gradual improvements in healthcare infrastructure. Brazil and Argentina remain the primary revenue-generating countries. The market is forecast to expand from USD 10.71 million in 2018 to USD 17.17 million by 2032, at a CAGR of 4.2%. While limited access to high-cost biologics remains a barrier, increasing adoption of generics and supportive government programs are expected to improve patient access and strengthen market growth.
Middle East
The Middle East holds 4.2% market share in 2024, with demand driven by advanced hospital networks in GCC countries and growing adoption of biologic therapies. Revenues are expected to climb from USD 9.41 million in 2018 to USD 14.56 million by 2032, growing at a CAGR of 4.3%. High healthcare spending in countries such as Saudi Arabia and the UAE contributes to regional expansion. However, limited penetration in non-GCC countries highlights a need for broader infrastructure development and investment in rare disease treatment programs.
Africa
Africa represents the smallest market, with 1.9% share in 2024, but shows steady growth potential. Revenues are projected to increase from USD 2.67 million in 2018 to USD 6.99 million by 2032, reflecting a CAGR of 4.6%. South Africa and Egypt lead the regional market, supported by gradually improving healthcare systems and growing awareness of rare diseases. Despite challenges related to affordability and limited specialized care facilities, international collaborations and NGO-led awareness initiatives are gradually expanding treatment access across the continent.
Market Segmentations:
By Type
Corticosteroids
Immunosuppressants
Monoclonal Antibodies
Plasma Exchange
Supportive Therapy
By Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By End-User
Home Healthcare Providers
Hospitals (Acute Episode Management)
Specialty Clinics (Ongoing Care Management)
By Region
North America(U.S., Canada, Mexico)
Europe(UK, France, Germany, Italy, Spain, Russia, Rest of Europe)
Asia Pacific(China, Japan, South Korea, India, Australia, Southeast Asia, Rest of Asia Pacific)
Latin America(Brazil, Argentina, Rest of Latin America)
Middle East(GCC Countries, Israel, Turkey, Rest of Middle East)
Africa(South Africa, Egypt, Rest of Africa)
Competitive Landscape
The Devic’s Syndrome Treatment Market is moderately consolidated, with a few key players driving innovation and market expansion. Companies such as Alexion Pharmaceuticals, F. Hoffmann-La Roche, Viela Bio, Chugai Pharmaceutical, and Teva Pharmaceutical Industries are at the forefront, leveraging strong portfolios in biologics and immunotherapies. Alexion leads with its approved biologic therapies that have set benchmarks in treatment efficacy, while Roche and Chugai continue to expand through robust R&D pipelines targeting monoclonal antibodies. Viela Bio, now part of Horizon Therapeutics, has strengthened its position through strategic acquisitions and niche product launches. Teva remains competitive by offering cost-effective immunosuppressants, ensuring wider market penetration. The competitive environment is shaped by continuous clinical trials, regulatory approvals, and collaborations with research institutes. Partnerships, licensing agreements, and regional expansions are common strategies, as companies aim to improve accessibility and address unmet needs in both developed and emerging markets.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In March 2024, the US FDA approved ULTOMIRIS (ravulizumab-cwvz) as the first long-acting C5 complement inhibitor for adults with anti-AQP4 antibody-positive NMOSD.
In August 2025, Alexion and AstraZeneca Rare Disease reached a Letter of Intent with Canada’s pCPA to list ULTOMIRIS on provincial formularies for NMOSD and gMG.
In April 2025, Amgen announced that UPLIZNA (inebilizumab-cdon) gained FDA approval for IgG4-related disease, with statements highlighting its broader potential in NMOSD and other autoimmune conditions.
Report Coverage
The research report offers an in-depth analysis based on Type, Distribution Channel, End User and Region. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
Monoclonal antibodies will continue to dominate as frontline therapies due to proven efficacy.
Biosimilars are expected to gain traction, improving affordability and patient access.
Personalized medicine will shape treatment decisions through biomarker-driven approaches.
Digital health platforms will enhance patient monitoring and therapy adherence.
Emerging markets will witness stronger adoption with improved healthcare infrastructure.
Collaborations between pharmaceutical companies and research institutes will expand clinical pipelines.
Home-based care models will grow as supportive therapies shift outside hospitals.
Government support and reimbursement reforms will expand treatment accessibility.
Investment in rare disease awareness will drive early diagnosis and intervention.
Strategic acquisitions and partnerships will intensify competition and global market presence.
CHAPTER NO. 1 : GENESIS OF THE MARKET
1.1 Market Prelude – Introduction & Scope
1.2 The Big Picture – Objectives & Vision
1.3 Strategic Edge – Unique Value Proposition
1.4 Stakeholder Compass – Key Beneficiaries CHAPTER NO. 2 : EXECUTIVE LENS
2.1 Pulse of the Industry – Market Snapshot
2.2 Growth Arc – Revenue Projections (USD Million)
2.3. Premium Insights – Based on Primary Interviews CHAPTER NO. 3 : DEVIC’S SYNDROME TREATMENT MARKET FORCES & INDUSTRY PULSE
3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown
3.6 Price Trend Analysis
3.6.1 Regional Price Trend
3.6.2 Price Trend by product CHAPTER NO. 4 : KEY INVESTMENT EPICENTER
4.1 Regional Goldmines – High-Growth Geographies
4.2 Product Frontiers – Lucrative Product Categories
4.3 Distribution Channel Sweet Spots – Emerging Demand Segments CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING
5.1 Momentum Metrics – Forecast & Growth Curves
5.2 Regional Revenue Footprint – Market Share Insights
5.3 Segmental Wealth Flow – Type & Distribution Channel Revenue CHAPTER NO. 6 : TRADE & COMMERCE ANALYSIS
6.1. Import Analysis by Region
6.1.1. Global Devic’s Syndrome Treatment Market Import Revenue By Region
6.2. Export Analysis by Region
6.2.1. Global Devic’s Syndrome Treatment Market Export Revenue By Region CHAPTER NO. 7 : COMPETITION ANALYSIS
7.1. Company Market Share Analysis
7.1.1. Global Devic’s Syndrome Treatment Market: Company Market Share
7.2. Global Devic’s Syndrome Treatment Market Company Revenue Market Share
7.3. Strategic Developments
7.3.1. Acquisitions & Mergers
7.3.2. New Product Launch
7.3.3. Regional Expansion
7.4. Competitive Dashboard
7.5. Company Assessment Metrics, 2024 CHAPTER NO. 8 : DEVIC’S SYNDROME TREATMENT MARKET – BY TYPE SEGMENT ANALYSIS
8.1. Devic’s Syndrome Treatment Market Overview by Type Segment
8.1.1. Devic’s Syndrome Treatment Market Revenue Share By Type
8.2. Corticosteroids
8.3. Immunosuppressants
8.4. Monoclonal Antibodies
8.5. Plasma Exchange
8.6. Supportive Therapy CHAPTER NO. 9 : DEVIC’S SYNDROME TREATMENT MARKET – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS
9.1. Devic’s Syndrome Treatment Market Overview by Distribution Channel Segment
9.1.1. Devic’s Syndrome Treatment Market Revenue Share By Distribution Channel
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies CHAPTER NO. 10 : DEVIC’S SYNDROME TREATMENT MARKET – BY END-USER SEGMENT ANALYSIS
10.1. Devic’s Syndrome Treatment Market Overview by End-user Segment
10.1.1. Devic’s Syndrome Treatment Market Revenue Share By End-user
10.2. Home Healthcare Providers
10.3. Hospitals (Acute Episode Management)
10.4. Specialty Clinics (Ongoing Care Management) CHAPTER NO. 11 : DEVIC’S SYNDROME TREATMENT MARKET – REGIONAL ANALYSIS
11.1. Devic’s Syndrome Treatment Market Overview by Region Segment
11.1.1. Global Devic’s Syndrome Treatment Market Revenue Share By Region
11.1.3. Regions
11.1.4. Global Devic’s Syndrome Treatment Market Revenue By Region
.1.6. Type
11.1.7. Global Devic’s Syndrome Treatment Market Revenue By Type
11.1.9. Distribution Channel
11.1.10. Global Devic’s Syndrome Treatment Market Revenue By Distribution Channel
11.1.12. End-user
11.1.13. Global Devic’s Syndrome Treatment Market Revenue By End-user CHAPTER NO. 12 : NORTH AMERICA DEVIC’S SYNDROME TREATMENT MARKET – COUNTRY ANALYSIS
12.1. North America Devic’s Syndrome Treatment Market Overview by Country Segment
12.1.1. North America Devic’s Syndrome Treatment Market Revenue Share By Region
12.2. North America
12.2.1. North America Devic’s Syndrome Treatment Market Revenue By Country
12.2.2. Type
12.2.3. North America Devic’s Syndrome Treatment Market Revenue By Type
12.2.4. Distribution Channel
12.2.5. North America Devic’s Syndrome Treatment Market Revenue By Distribution Channel
2.2.6. End-user
12.2.7. North America Devic’s Syndrome Treatment Market Revenue By End-user
2.3. U.S.
12.4. Canada
12.5. Mexico CHAPTER NO. 13 : EUROPE DEVIC’S SYNDROME TREATMENT MARKET – COUNTRY ANALYSIS
13.1. Europe Devic’s Syndrome Treatment Market Overview by Country Segment
13.1.1. Europe Devic’s Syndrome Treatment Market Revenue Share By Region
13.2. Europe
13.2.1. Europe Devic’s Syndrome Treatment Market Revenue By Country
13.2.2. Type
13.2.3. Europe Devic’s Syndrome Treatment Market Revenue By Type
13.2.4. Distribution Channel
13.2.5. Europe Devic’s Syndrome Treatment Market Revenue By Distribution Channel
13.2.6. End-user
13.2.7. Europe Devic’s Syndrome Treatment Market Revenue By End-user
13.3. UK
13.4. France
13.5. Germany
13.6. Italy
13.7. Spain
13.8. Russia
13.9. Rest of Europe CHAPTER NO. 14 : ASIA PACIFIC Devic’s SYNDROME TREATMENT MARKET – COUNTRY ANALYSIS
14.1. Asia Pacific Devic’s Syndrome Treatment Market Overview by Country Segment
14.1.1. Asia Pacific Devic’s Syndrome Treatment Market Revenue Share By Region
14.2. Asia Pacific
14.2.1. Asia Pacific Devic’s Syndrome Treatment Market Revenue By Country
14.2.2. Type
14.2.3. Asia Pacific Devic’s Syndrome Treatment Market Revenue By Type
14.2.4. Distribution Channel
14.2.5. Asia Pacific Devic’s Syndrome Treatment Market Revenue By Distribution Channel
14.2.5. End-user
14.2.7. Asia Pacific Devic’s Syndrome Treatment Market Revenue By End-user
14.3. China
14.4. Japan
14.5. South Korea
14.6. India
14.7. Australia
14.8. Southeast Asia
14.9. Rest of Asia Pacific CHAPTER NO. 15 : LATIN AMERICA DEVIC’S SYNDROME TREATMENT MARKET – COUNTRY ANALYSIS
15.1. Latin America Devic’s Syndrome Treatment Market Overview by Country Segment
15.1.1. Latin America Devic’s Syndrome Treatment Market Revenue Share By Region
15.2. Latin America
15.2.1. Latin America Devic’s Syndrome Treatment Market Revenue By Country
15.2.2. Type
15.2.3. Latin America Devic’s Syndrome Treatment Market Revenue By Type
15.2.4. Distribution Channel
15.2.5. Latin America Devic’s Syndrome Treatment Market Revenue By Distribution Channel
15.2.6. End-user
15.2.7. Latin America Devic’s Syndrome Treatment Market Revenue By End-user
15.3. Brazil
15.4. Argentina
15.5. Rest of Latin America CHAPTER NO. 16 : MIDDLE EAST DEVIC’S SYNDROME TREATMENT MARKET – COUNTRY ANALYSIS
16.1. Middle East Devic’s Syndrome Treatment Market Overview by Country Segment
16.1.1. Middle East Devic’s Syndrome Treatment Market Revenue Share By Region
16.2. Middle East
16.2.1. Middle East Devic’s Syndrome Treatment Market Revenue By Country
16.2.2. Type
16.2.3. Middle East Devic’s Syndrome Treatment Market Revenue By Type
16.2.4. Distribution Channel
16.2.5. Middle East Devic’s Syndrome Treatment Market Revenue By Distribution Channel
16.2.6. End-user
16.2.7. Middle East Devic’s Syndrome Treatment Market Revenue By End-user
16.3. GCC Countries
16.4. Israel
16.5. Turkey
16.6. Rest of Middle East CHAPTER NO. 17 : AFRICA DEVIC’S SYNDROME TREATMENT MARKET – COUNTRY ANALYSIS
17.1. Africa Devic’s Syndrome Treatment Market Overview by Country Segment
17.1.1. Africa Devic’s Syndrome Treatment Market Revenue Share By Region
17.2. Africa
17.2.1. Africa Devic’s Syndrome Treatment Market Revenue By Country
17.2.2. Type
17.2.3. Africa Devic’s Syndrome Treatment Market Revenue By Type
17.2.4. Distribution Channel
17.2.5. Africa Devic’s Syndrome Treatment Market Revenue By Distribution Channel
17.2.6. End-user
17.2.7. Africa Devic’s Syndrome Treatment Market Revenue By End-user
17.3. South Africa
17.4. Egypt
17.5. Rest of Africa CHAPTER NO. 18 : COMPANY PROFILES
18.1. Alexion Pharmaceuticals, Inc.
18.1.1. Company Overview
18.1.2. Product Portfolio
18.1.3. Financial Overview
18.1.4. Recent Developments
18.1.5. Growth Strategy
18.1.6. SWOT Analysis
18.2. F. Hoffmann-La Roche Ltd.
18.3. Viela Bio, Inc.
18.4. Chugai Pharmaceutical Co., Ltd.
18.5. Teva Pharmaceutical Industries Ltd.
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions
What is the current market size for Devic’s Syndrome Treatment Market, and what is its projected size in 2032?
The Devic’s Syndrome Treatment Market size reached USD 246.32 million in 2024 and is forecasted to achieve USD 374.34 million by 2032, demonstrating consistent growth.
At what Compound Annual Growth Rate is the Devic’s Syndrome Treatment Market projected to grow between 2025 and 2032?
The Devic’s Syndrome Treatment Market is expected to expand at a steady CAGR of 5.45% during the forecast period of 2025 to 2032, ensuring sustainable development.
Which Devic’s Syndrome Treatment Market segment held the largest share in 2024?
In 2024, monoclonal antibodies dominated the market with around 42% share, supported by strong relapse prevention efficacy, regulatory approvals, and expanding clinical adoption globally.
What are the primary factors fueling the growth of the Devic’s Syndrome Treatment Market?
Key growth drivers include rising prevalence of NMOSD, advancements in biologic therapies, and supportive government reimbursement policies improving patient access and driving treatment adoption worldwide.
Who are the leading companies in the Devic’s Syndrome Treatment Market?
Prominent players include Alexion Pharmaceuticals, F. Hoffmann-La Roche, Viela Bio, Chugai Pharmaceutical, and Teva Pharmaceutical Industries, leading innovation and global expansion in biologics and immunotherapies.
Which region commanded the largest share of the Devic’s Syndrome Treatment Market in 2024?
North America led the market with a 44.9% share in 2024, driven by advanced healthcare infrastructure, high biologic adoption, strong reimbursement frameworks, and clinical research.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
Document Capture Software Market size was valued at USD 16,300.00 million in 2018 to USD 22,191.04 million in 2024 and is anticipated to reach USD 43,330.09 million by 2032, at a CAGR of 8.78% during the forecast period.
The AC Hose Market was valued at USD 3,728 million in 2024 and is projected to reach USD 5,852.8 million by 2032, growing at a CAGR of 5.8% during the forecast period.
Water Tube Industrial Boiler Market size was valued at USD 7.72 billion in 2024 and is anticipated to reach USD 10.98 billion by 2032, at a CAGR of 4.5% during the forecast period.
Fire Tube Chemical Boiler Market was valued at USD 1.9 billion in 2024 and is projected to reach USD 2.6 billion by 2032, expanding at a CAGR of 4.1% during the forecast period.
Medium Voltage Transmission Substation Market size was valued at USD 28.06 billion in 2024 and is anticipated to reach USD 34.46 billion by 2032, at a CAGR of 2.6% during the forecast period.
Asia Pacific Industrial Scaffolding market size was valued at USD 6,975.77 million in 2018, grew to USD 8,855.52 million in 2024, and is anticipated to reach USD 14,935.98 million by 2032, at a CAGR of 6.75% during the forecast period.
Europe Industrial Scaffolding Market was valued at USD 2,598.26 million in 2018, grew to USD 3,048.15 million in 2024, and is anticipated to reach USD 4,493.55 million by 2032, at a CAGR of 4.97% during the forecast period.
Global Industrial Scaffolding market size was valued at USD 14,121.0 million in 2018, reached USD 17,541.0 million in 2024, and is anticipated to reach USD 28,121.1 million by 2032, at a CAGR of 6.10% during the forecast period.
Latin America Industrial Scaffolding Market size was valued at USD 828.90 million in 2018, grew to USD 1,018.96 million in 2024, and is anticipated to reach USD 1,506.45 million by 2032, at a CAGR of 5% during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$6999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
